Kiora Pharmaceuticals (KPRX) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kiora Pharmaceuticals (KPRX) has outperformed Theriva Biologics (TOVX) over the past year, losing 7.3% versus a loss of 49.5%. Over five years, KPRX leads with a -99.6% price change compared with -99.8% for TOVX. Kiora Pharmaceuticals is the larger company by market cap ($11.2 million vs $10.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KPRX | TOVX |
|---|---|---|
| Share price | $2.53 | $0.2271 |
| Market cap | $11.19M | $10.42M |
| 1-day change | 0.00% | -2.95% |
| YTD return | +28.43% | +8.14% |
| 1-year return | -7.33% | -49.53% |
| 5-year return | -99.64% | -99.79% |
| P/E ratio (TTM) | — | 0.30 |
| EPS (TTM) | $-2.46 | $0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.91 | $0.86 |
| 52-week low | $1.77 | $0.16 |
| Distance from 52-week high | -13.06% | -73.59% |
| Analyst consensus | none | none |
| Avg. price target upside | +374.31% | +1000.84% |
| Average volume | 17.41K | 530.02K |
| Shares outstanding | 4.42M | 45.89M |
| Employees | 13 | 15 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KPRX has outperformed TOVX by 42.2 percentage points over the past year.
About Kiora Pharmaceuticals
KPRX stock →Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
Healthcare · Biotechnology · 13 employees
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Healthcare · Biotechnology · 15 employees
KPRX vs TOVX FAQ
Which is bigger, Kiora Pharmaceuticals or Theriva Biologics?
Kiora Pharmaceuticals (KPRX) is larger, with a market capitalization of $11.19M compared with $10.42M for Theriva Biologics (TOVX).
Which stock has performed better over the past year, KPRX or TOVX?
KPRX returned -7.33% over the past 12 months, compared with -49.53% for TOVX (price return, excluding dividends). Past performance does not predict future results.
Are Kiora Pharmaceuticals and Theriva Biologics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.